期刊文献+

血浆纤溶酶原激活物抑制物1与胰岛素抵抗的相关性研究 被引量:9

The relationship between PAI-1 and insulin resistance syndrome
下载PDF
导出
摘要 目的 探讨血浆纤溶酶原激活物抑制物 1(plasm inogen activitor inhibitor one,PAI- 1)活性及其基因启动子区 4 G/ 5 G多态性与胰岛素抵抗综合征的关系。 方法 应用等位基因特异性PCR扩增技术 ,对胰岛素抵抗综合征患者 (16 0例 )和对照组 (90例 ) PAI- 14 G/ 5 G多态位点的基因型进行检测 ,用发色底物法测血浆 PAI- 1活性。 结果  (1)胰岛素抵抗综合征患者 PAI- 1活性明显升高 ,空腹胰岛素、空腹血糖、甘油三酯与 PAI- 1活性升高密切相关 (P<0 .0 1)。 (2 )对照组和胰岛素抵抗综合征患者 ,4 G/ 5 G基因型频率分别为 0 .5 2和 0 .4 8,两组比较无明显差异 (P>0 .0 5 ) ,但胰岛素抵抗综合征不同基因型者 PAI- 1活性差异显著 (P<0 .0 1) ,4 G/ 4 G基因型者 PAI- 1活性高于 4 G/ 5 G和5 G/ 5 G基因型者 (P<0 .0 1)。 (3)血糖、甘油三酯对 PAI- 1活性的调节受基因型的影响。 4 G/ 4 G基因型者血糖、甘油三酯与 PAI- 1活性密切相关 (P<0 .0 1) ,而 4 G/ 5 G和 5 G/ 5 G基因型者血糖、甘油三酯与 PAI- 1活性无明显相关 (P>0 .0 5 )。 (4)胰岛素对 PAI- 1活性的影响无基因型依赖性。 结论 PAI- 1活性升高是胰岛素抵抗综合征患者的特征之一 ,免疫反应性胰岛素、血糖、甘油三酯与 PAI- 1活性升高有关 ,血糖? Objective To investigate the corelationship between PAI 1 activity and PAI 1 promoter 4G/5G polymorphism with insulin resistance syndrome. Methods The 4G/5G allele polymorphism in the PAI 1 gene promoter region were genotyped with an allele specific PCR in patients with insulin resistance syndrome (160)and controls (90).The activity of PAI 1 was assayed by chromogenic substrate method. Results (1)PAI 1 activity was higher in patients with insulin resistance syndrome than in controls.Insulin,blood glucose and triglyceride were responsible for it. (2)Though the frequency of PAI 1 4G/4G genotype was equal in two groups,the plasma PAI 1 activity was significantly different in different genotypes.It was higher in 4G/4G group than in 4G/5G( P <0.01) and 5G/5G group( P <0.01). (3)The level of PAI 1 activity regulated by blood glucose and triglyceride depended on PAI 1 4G/5G genotype. The levels of blood glucose and triglyceride were significantly associated with PAI 1 activity only in 4G/4G group. (4)The plasma PAI 1 activity was regulated by insulin in each group. Conclusion Increased PAI 1 activity caused by insulin ,blood glucose and triglyceride is a character of insulin resistance syndrome. The presence of the 4G allele of PAI 1 gene and higher blood glucose and triglyceride concentrations are associated with higher level of PAI 1 activity and may be involved in the generation of insulin resistance syndrome.
出处 《中国糖尿病杂志》 CAS CSCD 2002年第4期222-226,共5页 Chinese Journal of Diabetes
基金 山东省科委资助项目 (2 0 0 0鲁科 2 96)
关键词 血浆纤溶酶原激活物抑制物1 胰岛素抵抗 相关性 PAI-1 基因 PAI 1 4G/5G genotype Insulin resistance syndrome
  • 相关文献

参考文献14

  • 1[1]McCormack LJ, Nagi DK, Grant PJ, et al. Plasminogen activator inhibitor-1 genotype (4G/5G) in Pima Indians:relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome. Diabetologia,1996.1512-1518.
  • 2[2]Mojca S, Pavel U, Bernd RB, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 gene:relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost,1998,79:975-979.
  • 3[3]Yumiko M, Mitsuru M, Yasuo I, et al.Genotype frequency of plasminogen activator inhibitor-1(PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.International J Hematol,1999,69:43-47.
  • 4[4]Andreas G, Jana L, Werner H, et al.The 4G/5G genotype of the plasminogen activator inhibitor-1 gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost,1999,82:1121-1126.
  • 5[5]Grancha S, Esrelles A, Aznar J, et al. Plasminogen activator inhibitor-1(PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.Thromb Haemost,1999, 81:516-21.
  • 6[6]Maria TS, Antonio G, Gilvaurizio P, et al. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost,1998,80:956-60.
  • 7[7]Michael W, Mansfield J. Environmental and genetic factors in relation to elevated circulating levels of PAI-1 in caucasian patients with type two diabetes.Thromb Haemost,1997,79:842-847
  • 8[8]Potter BJ, Kluft C, Radder JK, et al.The cardiovascular risk factor PAI-1 is related to insulin resistance. Metabolism,1993,43:945-949.
  • 9[9]Haffner SM, DAgostino R Jr, Tracy R, et al.Sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care, 1999, 22:4,562-568.
  • 10[10]Testa R, Bonfigli AR, Pieri C, et al. A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications. Int J Clin Lab Res, 1998, 28:3, 187-191.

同被引文献75

  • 1严为宏,方晶,沈仙娣,李威,胡钧培.脑梗死与纤溶酶原激活抑制物-1的相关性[J].中国临床康复,2005,9(5):97-99. 被引量:4
  • 2魏蓉,吴国亭,于永春,汪纯,盛春君,韩玉麒.2型糖尿病PAI-1基因启动子区4G/5G基因多态性与胰岛素抵抗[J].同济大学学报(医学版),2005,26(4):73-77. 被引量:1
  • 3赵君利,陈子江,赵跃然,赵力新,王来成,唐蓉,马增香.纤溶酶原激活物抑制因子1基因启动子区4G和5G多态基因型分布及其与多囊卵巢综合征的相关性研究[J].中华妇产科杂志,2005,40(8):528-531. 被引量:17
  • 4Zanella MT, Ribeiro AB. The role of angiotensin Ⅱ antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clin Ther, 2002, 24(7) : 1019 - 1034.
  • 5Shichiri M, Hirata Y. Serum uric acid level and fractional excretion of urate in fluid and electrolyte disturbances, Rinsho Byori,1999,47(5):417-423.
  • 6盂昭亨.痛风.北京:北京医科大学、中国协和医科大学联合出版社,1998. 211.
  • 7Shcherbak AV, Balkarov IM, Kozlovskaia LV. Urine fibrinolytic activity as an indicator of kidney damage in uric acid metabolic imbalance. Ter Arkh, 2001,73(6) : 34 - 37.
  • 8Parsons MW, Barber PA, Desmond PM. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol,2002,52( 1 ) :20-28.
  • 9Baird TA, Parsons MW, Phanh T. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke, 2003,34(9) :2208-2214.
  • 10Tandberg Askevold E, Naess H, Thomassen L. Predictors for recanalization after intravenous thrombolysis in acute ischemic stroke. Stroke Cerebrovasc Dis,2007,16 ( 1 ) :21-24.

引证文献9

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部